SCHEMBL6440532

SCHEMBL6440532

CSc1nc(N)nc(-c2cccc(C)c2)c1C#N

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.72
MAPT P10636 2/20 0.72
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
ADORA1 P30542 13/20 0.53
ADORA2A P29274 11/20 0.53
ADORA2B P29275 5/20 0.53
ALDH1A1 P00352 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 2/20 0.47
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440876 0.86 MAPT (0.70) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL6442594 0.85 ADORA1 (0.71) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL6441069 0.84 RXFP1 (1.00) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL27573259 0.83 ADORA1 (0.67) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL6441246 0.79 ADORA1 (0.69) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL6440513 0.77 ADORA1 (0.65) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL6444900 0.77 NPSR1 (0.64) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL6441330 0.75 ADORA1 (0.69) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL5039781 0.75 ADORA1 (0.59) RXFP1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL6441875 0.75 ADORA1 (0.76) RXFP1MAPTCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 RXFP1 390/4885MAPT 1878/4885CYP1A2 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.